|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 17, 2021 )
Market Overview
The global cardiometabolic monitoring products market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
The cardiometabolic syndrome is a grouping of metabolic dysfunctions that includes insulin resistance and reduced glucose tolerance, atherogenic dyslipidemia, hypertension, and intra-abdominal obesity (IAA).
View full report: https://www.datamintelligence.com/research-report/cardiometabolic-monitoring-products-market
Market Dynamics
The factors driving the cardiometabolic monitoring products market are the increasing incidence of cardiovascular diseases and the technological advancement in this field in the forecast period.
Increasing incidence of cardiovascular diseases is estimated to drive the market growth
Cardiometabolic disorders (CMDs) are the leading cause of death worldwide. Cardiovascular disease (CVD), diabetes mellitus, and chronic renal failure are examples. CMDs are mostly caused by an unhealthy lifestyle, with physical inactivity, smoking, and an improper diet being key risk factors. According to WHO, cardiovascular diseases are the leading cause of death worldwide, killing an estimated 17.9 million people per year. CVDs are a collection of heart and blood vessel disorders, including coronary heart disease, cerebrovascular disease, rheumatic heart disease, and others. Heart attacks and strokes account for more than four out of every five CVD deaths, and one-third of these deaths occur in adults under 70. A common metabolic condition is a cardiometabolic syndrome. Epidemiologic research has linked cardiometabolic syndrome to an elevated risk of coronary heart disease, ischemic stroke, cardiovascular mortality, and overall mortality. There is additional evidence that cardiometabolic syndrome is a risk factor for myocardial metabolism abnormalities, cardiac dysfunction, and atrial fibrillation arrhythmias.
The most frequent type of heart illness is coronary heart disease, which killed 360,900 people in 2019. CAD affects approximately 18.2 million persons aged 20 and up (about 6.7 percent ). Adults under the age of 65 accounts for almost two-tenths of all CAD deaths. Hence, with increasing incidence of CAD cases is expected to drive the cardiometabolic monitoring products market.
The technological advancement in this field is expected to drive market growth in the forecast period
While there are multiple technology landscapes for (multi-) disease diagnostics for infectious diseases at various levels of care, there are none for NCD diagnostics to treat cardiometabolic disorders. As a result, the Foundation for Innovative New Diagnostics (FIND) established the Foundation for Innovative New Diagnostics (FIND) with technical assistance from the World Health Organization. The World Health Organization (WHO) created this panorama of multi-parameter point-of-care (POC) devices that can provide Cardiometabolic illness diagnosis and monitoring at PHC facilities. Raised blood pressure, elevated blood glucose, raised blood lipids, and obesity are all risk factors for cardiometabolic disease and obesity.
Several interventions that can be used to detect and manage cardiometabolic risk are included in the WHO Package of Essential Noncommunicable Disease Interventions for Primary Health Care in Low-Resource Settings and the WHO Model List of Essential In Vitro Diagnostics. For example, On June 9, 2021, Through the ACC Innovation Program, the ACC and cliexa, a Denver-based business, teamed to build cliexa-Pulse, a home health monitoring platform. Cliexa-PULSE is intended to help clinicians manage atrial fibrillation, hypertension, heart failure, and other cardiovascular disorders by tracking symptoms, drugs, and daily activities.
The high cost and challenges of cardiometabolic diseases are expected to hamper the market growth
The aim to simplify the complex management of cardiometabolic disorders (CMD) has resulted in the discovery of numerous biomarkers; nevertheless, there are no obvious explanations for their involvement in the prevention, diagnosis, or prognosis of these diseases. Molecules linked to disease pathways serve as valid disease surrogates as well as well-fitting CMD biomarkers. From human and animal models, data from multi-omics types (genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, and nutrigenomics) have become available to solve this difficulty.
Cardiometabolic risks (CMRs) have risen to pandemic proportions during the last three decades. No country has been able to reduce, reverse, or halt the rise in the incidence or prevalence of chronic metabolic disorders. According to the study, the yearly cardiometabolic illness cost linked with poor nutrition is $301 per person and $50.4 billion for the US population, accounting for 18.2 percent of overall cardiometabolic disease costs.
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. The Covid-19 pandemic, in particular, has affected the diagnostics business. This has negatively affected the global cardiometabolic monitoring products market.
Market Segmentation
Global Cardiometabolic Monitoring Products Market - By Product
• POC Analyzers
• Cholesterol Analyzer
• Biochemistry Analyzer
• Holter monitor
• ECG
Global Cardiometabolic Monitoring Products Market - By Indication
• Cardiovascular Diseases
• Diabetes
• Others
Global Cardiometabolic Monitoring Products Market - By End-User
• Hospitals
• Diagnostic Centers
• Ambulatory Clinics
Global Cardiometabolic Monitoring Products Market - By Region
• North America
• Europe
• South America
• Asia Pacific
• Middle East and Africa
Download free sample: https://www.datamintelligence.com/download-sample/cardiometabolic-monitoring-products-market
On May 21, 2020, EKF Diagnostics added a new addition to its Diabetes Care range in the United States. The STAT-Site WB, a dual-use whole blood -ketone and glucose metre designed for professional usage in diabetes treatment. The new CLIA-waived handheld analyzer from the United States Food and Drug Administration (FDA) reliably and efficiently delivers results in five to ten seconds. It can be used in point-of-care (POC) and Certificate of Waiver settings such as physicians' offices, clinics, and other non-traditional Diabetes locations.
Global Cardiometabolic Monitoring Products Market Competitive Landscape
The global cardiometabolic monitoring products market is highly competitive with the rising incidence of cardiovascular diseases and increasing demand for point of care devices.
Major key players in the global cardiometabolic monitoring products market are Abbott Laboratories, Callegari, Diasys, Tascom, Jana Care, Medical System Biotech, MNCHIP, Nova Biomedical, Roche Diagnostics and Siemens.
Abbott Laboratories
Overview: Abbott is a global healthcare firm dedicated to assisting people at all stages of life to live more fully. With leading businesses and products in diagnostics, medical devices, nutritional, and branded generic medications, their portfolio of life-changing technology spans the healthcare spectrum. Their 109,000 colleagues serve more than 160 countries.
Product Portfolio: The company’s point of care products consists of Cholestech Ldx™ Analyzer and AFINION™ 2.
Key Development: On May 31, 2018, Abbott launched the afinionTM 2 analyzer, the latest iteration of the Afinion test system, in the United States. The Afinion 2 expands on Abbott's legacy in diabetes care by providing patients with health information that they can discuss with their clinicians in a single visit.
Why Purchase the Report?
Visualize the composition of the global cardiometabolic monitoring products market Segmentation By Product , By Indication and End-User highlighting the key commercial assets and players.
Identify commercial opportunities in the global cardiometabolic monitoring products market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global cardiometabolic monitoring products market - level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global cardiometabolic monitoring products market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.
Target Audience
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers
Topic's you may be interested, Flavored Syrup Market, Software as a Medical Devices Market, Bacteriological Testing Market, Urinalysis Testing Products Market, Benzodiazepine Drugs Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
